The drug, which garnered national attention in March when it was touted by President Donald Trump, has been a subject of scrutiny as conflicting studies emerge on its efficacy in treating COVID-19. Small studies suggesting the drug could be a helpful treatment for the disease have been outweighed by larger studies revealing evidence that the drug was not effective and caused heart problems in some COVID-19 patients.
WHO’s announcement comes two days after the FDA rescinded its emergency use authorization for hydroxychloroquine and chloroquine, citing the same reasons as WHO.
More articles on pharmacy:
FDA warns of potential drug interaction with remdesivir
Walmart buys prescription management tech from CareZone
Steroid could reduce COVID-19 deaths: 5 things to know
The World Health Organization has pulled malaria drug hydroxychloroquine from its global study assessing possible treatments for COVID-19, according to a June 17 CNBC report.
The drug, which garnered national attention in March when it was touted by President Donald Trump, has been a subject of scrutiny as conflicting studies emerge on its efficacy in treating COVID-19. Small studies suggesting the drug could be a helpful treatment for the disease have been outweighed by larger studies revealing evidence that the drug was not effective and caused heart problems in some COVID-19 patients.
WHO’s announcement comes two days after the FDA rescinded its emergency use authorization for hydroxychloroquine and chloroquine, citing the same reasons as WHO.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
